 | Polyplus-transfection SA BIOPARC Boulevard Sébastien Brant BP 90018 67400 Illkirch France Tel.: +33 (0)3 90 40 61 80 Fax : +33 (0)3 90 40 61 81 Website: http://www.polyplus-transfection.com/ |
Polyplus-transfection is a research-focused biotechnology company developing and marketing innovative solutions for transfection and therapies based on nucleic acid delivery.
Transfection allows the introduction of nucleic acids, such as a gene or small interfering RNA (siRNA), into cells using chemical compounds. The technique is widely used in experimental research and in protein production.
Introducing a gene into a cell nucleus triggers the expression of the corresponding protein. Conversely, transferring siRNA will block the production of a protein. Inappropriate gene expression is the root cause of numerous diseases. As a result, the ability to control those genes through gene therapy or RNA interference opens up new therapeutic approaches where efficient intra-cellular drug transfer is key to success.
Using its know-how in nucleic acid delivery, the R&D department at Polyplus-transfection is focused on the development of innovative synthetic compounds designed to take account of the latest advances in the transfer of biomolecules, especially the in vivo delivery of small interfering RNA. Polyplus-transfection is one of the technology leaders in the transfection market.
Polyplus-transfection has established a number of R&D partnerships with biotechnology companies involved in therapeutics. It also plays an active role in European research networks such as GIANT (Gene therapy, and Integrated Approach to Neoplastic Treatment) and RIGHT (RNA Interference Technology as Human Therapeutic Tool).
Polyplus-transfection recently extended its field of expertise to the development of new cationic oligonucleotides, ZNA (Zip Nucleic Acid), for molecular biology and diagnostics.Source: Polyplus-transfection
